Clinical Trials Directory

LIPS-A: Lung Injury Prevention Study With Aspirin

The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.

Stanford is now accepting new patients for this trial.



  • drug : Lactose powder
  • drug : Aspirin

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Adult patients (age > 18) admitted to the hospital through the emergency department (ED) - At high risk of developing acute lung injury (ALI) Lung Injury Prediction Score (LIPS) greater than or equal to 4

External Links

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rosemary Vojnik

Footer Links: